AC
SLN

AXQ Capital’s Silence Therapeutics SLN Stock Holding History

AXQ Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+12,566
New +$88.4K 0.02% 770

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

AXQ Capital's SLN Position: Q2 2026 in Review

AXQ Capital opened a new position in Silence Therapeutics (SLN) in Q2 2026: 12,566 shares worth $138K. The stake represents 0.02% of the portfolio and ranks #770 among its holdings.

72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • AXQ Capital held 12,566 shares of Silence Therapeutics worth $138K as of Q2 2026.
  • Silence Therapeutics was a new AXQ Capital position in Q2 2026.
  • Silence Therapeutics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #770 holding.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.